Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors

被引：5
|
作者：
Duran, I.
Hotte, S.
Chen, E.
Hirte, H.
MacLean, M.
Turner, S.
Pond, G.
Wright, J.
Dancey, J.
Siul, L.
机构：
[1] Princess Margaret Hosp Phase II Consortium, Toronto, ON, Canada
[2] Natl Canc Inst, Bethesda, MD USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70555-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
550
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [1] Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors
    Duran, Ignacio
    Hotte, Sebastien J.
    Hirte, Holger
    Chen, Eric X.
    MacLean, Martha
    Turner, Sandra
    Duan, Lixia
    Pond, Gregory R.
    Lathia, Chetan
    Walsh, Scott
    Wright, John J.
    Dancey, Janet
    Siu, Lillian L.
    CLINICAL CANCER RESEARCH, 2007, 13 (16) : 4849 - 4857
  • [2] Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors
    Kao, Chien-Chang
    Ho, Ching-Liang
    Yang, Ming-Hsin
    Tsai, Yi-Ta
    Liu, Shu-Yu
    Chang, Ping-Ying
    Wu, Yi-Ying
    Chen, Jia-Hong
    Yehn, Ren-Hua
    Dai, Ming-Shen
    Chen, Yeu-Chin
    Sun, Guang-Huan
    Cha, Tai-Lung
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (08)
  • [3] A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors.
    Ma, CX
    Croghan, G
    Reid, J
    Hanson, L
    Mandrekar, S
    Marks, R
    Adjei, A
    Furth, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192S
  • [4] Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors.
    Garrido-Laguna, I.
    Kurzrock, R.
    Wheler, J. J.
    Falchook, G. S.
    Piha-Paul, S. A.
    Fu, S.
    Naing, A.
    Hinojosa, C.
    Mistry, R.
    Scamardo, A.
    Culotta, K. S.
    Ekmekcioglu, S.
    Wen, S.
    Camacho, L. H.
    Ivy, S. P.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Phase I Trial of Sorafenib in Combination With 5-Fluorouracil/Leucovorin in Advanced Solid Tumors
    Shacham-Shmueli, Einat
    Geva, Ravit
    Figer, Arie
    Bulocinic, Sarah
    Nalbandyan, Karen
    Shpigel, Shulim
    Atsmon, Jacob
    Brendel, Erich
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 656 - 669
  • [6] Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors
    Erich Brendel
    Matthias Ludwig
    Chetan Lathia
    Caroline Robert
    Stanislas Ropert
    Jean-Charles Soria
    Jean-Pierre Armand
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 53 - 61
  • [7] Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors
    Brendel, Erich
    Ludwig, Matthias
    Lathia, Chetan
    Robert, Caroline
    Ropert, Stanislas
    Soria, Jean-Charles
    Armand, Jean-Pierre
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 53 - 61
  • [8] A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    Nimeiri, H. S.
    Vargo, M. T.
    Bergsland, E. K.
    Ko, A. H.
    Munster, P. N.
    Reinert, A.
    Mulcahy, M. F.
    Benson, A. B.
    Venook, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort
    Quintela-Fandino, Miguel
    Le Tourneau, Christophe
    Duran, Ignacio
    Chen, Eric X.
    Wang, Lisa
    Tsao, Ming
    Bandarchi-Chamkhaleh, Bizhan
    Pham, Nhu-Ann
    Do, Trevor
    MacLean, Martha
    Nayyar, Rakesh
    Tusche, Michael W.
    Metser, Ur
    Wright, John J.
    Mak, Tak W.
    Siu, Lillian L.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (03) : 751 - 760
  • [10] A Phase I study of sorafenib in combination with capecitabine in patients with advanced, solid tumors
    Awada, A.
    Gil, T.
    Burk, K.
    Vanhamme, J.
    Mancini, I.
    Besse, T.
    Brendel, E.
    Matthys, A.
    Piccart, M.
    Hendlisz, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 33 - 34
12345